CA2034484A1 - Radio-immunotherapie faisant appel a des emissions de particules-d - Google Patents

Radio-immunotherapie faisant appel a des emissions de particules-d

Info

Publication number
CA2034484A1
CA2034484A1 CA2034484A CA2034484A CA2034484A1 CA 2034484 A1 CA2034484 A1 CA 2034484A1 CA 2034484 A CA2034484 A CA 2034484A CA 2034484 A CA2034484 A CA 2034484A CA 2034484 A1 CA2034484 A1 CA 2034484A1
Authority
CA
Canada
Prior art keywords
radioimmunotherapy
alpha
compositions
immunoconjugates
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2034484A
Other languages
English (en)
Other versions
CA2034484C (fr
Inventor
Maurits W. Geerlings
Franciscus M. Kaspersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2034484A1 publication Critical patent/CA2034484A1/fr
Application granted granted Critical
Publication of CA2034484C publication Critical patent/CA2034484C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'emploi d'Actinium ou d'un des éléments de sa filiation en radioimmunothérapie. L'invention concerne également des immunoconjugués comprenant un isotope, un agent de chélation et un anticorps de localisation lente. L'invention concerne en outre des compositions pharmaceutiques comprenant lesdits immunoconjugués, ainsi que de telles compositions comprenant un ou plusieurs agents d'épuration. Les compositions de l'invention sont particulièrement utiles dans le traitement de micrométastases en thérapie auxiliaire, ainsi que dans le traitement de tumeurs localisées.
CA002034484A 1989-06-19 1990-06-19 Radio-immunotherapie faisant appel a des emissions de particules-d Expired - Lifetime CA2034484C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP89.201591.8 1989-06-19
EP89201591 1989-06-19
PCT/EP1990/000990 WO1990015625A1 (fr) 1989-06-19 1990-06-19 RADIOIMMUNOTHERAPIE UTILISANT UNE EMISSION DE PARTICULES $g(a)

Publications (2)

Publication Number Publication Date
CA2034484A1 true CA2034484A1 (fr) 1990-12-20
CA2034484C CA2034484C (fr) 2000-08-15

Family

ID=8202415

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002034484A Expired - Lifetime CA2034484C (fr) 1989-06-19 1990-06-19 Radio-immunotherapie faisant appel a des emissions de particules-d

Country Status (11)

Country Link
US (1) US5246691C1 (fr)
EP (1) EP0429624B1 (fr)
JP (1) JPH089553B2 (fr)
KR (1) KR0179645B1 (fr)
AU (1) AU629367B2 (fr)
CA (1) CA2034484C (fr)
DE (1) DE69007430T2 (fr)
DK (1) DK0429624T3 (fr)
ES (1) ES2053196T3 (fr)
FI (1) FI98707C (fr)
WO (1) WO1990015625A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403771B1 (en) * 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (fr) * 1992-07-27 2004-03-16 Maurits W. Geerlings Methode et moyens pour une therapie ciblee
EP0746761A4 (fr) * 1993-03-12 1997-02-26 Akzo America Inc Processus d'extraction du radon 220 d'un melagne d'isotopes radioactifs
LU88636A1 (de) * 1995-07-03 1997-01-03 Euratom Verfahren zur Erzeugung von Actinium-225
LU88637A1 (de) * 1995-07-03 1997-01-03 Euratom Verfahren zur Erzeugung von Actinium-225 und Wismut-213 durch Bestrahlung von Radium-226 mit hochenergetischen Gammaquanten
PT842668E (pt) * 1996-11-15 2003-01-31 Euratom Metodo ex-corpore de tratamento de celulas humanas sanguineas
US5809394A (en) * 1996-12-13 1998-09-15 Battelle Memorial Institute Methods of separating short half-life radionuclides from a mixture of radionuclides
US6117413A (en) * 1997-11-12 2000-09-12 Battelle Memorial Institute Radionuclide-binding compound, a radionuclide delivery system, a method of making a radium complexing compound, a method of extracting a radionuclide, and a method of delivering a radionuclide
WO1999036105A2 (fr) * 1998-01-16 1999-07-22 Mca Development B.V. Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
US6696551B1 (en) 1999-03-23 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services 225Ac-HEHA and related compounds, methods of synthesis and methods of use
EP1289570B1 (fr) * 2000-06-16 2008-09-10 Sloan-Kettering Institute For Cancer Research Encapsulation liposomale d'emetteurs alpha et utilisations
US6852296B2 (en) * 2001-06-22 2005-02-08 Pg Research Foundation Production of ultrapure bismuth-213 for use in therapeutic nuclear medicine
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
WO2004062722A2 (fr) * 2003-01-08 2004-07-29 Sloan Kettering Institute For Cancer Research Prevention de toxicite systemique durant la radiotherapie immunologique pour des cancers a dissemination intravasculaire
NZ595758A (en) * 2003-04-15 2013-02-22 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
DE102004022200B4 (de) * 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US7618627B2 (en) 2004-06-03 2009-11-17 The Regents Of The University Of California Method of increasing radiation sensitivity by inhibition of beta one integrin
US7157061B2 (en) * 2004-09-24 2007-01-02 Battelle Energy Alliance, Llc Process for radioisotope recovery and system for implementing same
US7736610B2 (en) * 2004-09-24 2010-06-15 Battelle Energy Alliance, Llc Actinium radioisotope products of enhanced purity
DE102006008023B4 (de) * 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
CA2950532C (fr) * 2006-09-08 2018-10-23 Actinium Pharmaceuticals, Inc. Procede pour la purification du radium de differentes sources
CN104710504B (zh) 2009-07-22 2019-09-13 锕医药股份有限公司 用于制备放射性免疫缀合物的方法
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
EP3409297A1 (fr) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. Générateur optimal de 225-actinium - 213-bismuth pour la radio-immunothérapie à particules alpha
WO2019057598A1 (fr) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. Générateur optimal de 225actinium--213bismuth pour la radio-immunothérapie à particules alpha
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
EP4577578A1 (fr) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Molécules de liaison à dll3 et leurs utilisations
WO2026024644A1 (fr) 2024-07-23 2026-01-29 Abdera Therapeutics Inc. Polypeptides de liaison à 5t4 et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
EP0282057A3 (fr) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Produits associés chémo-radio-immunologiques
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates

Also Published As

Publication number Publication date
KR920700690A (ko) 1992-08-10
AU629367B2 (en) 1992-10-01
DE69007430D1 (de) 1994-04-21
JPH04500366A (ja) 1992-01-23
JPH089553B2 (ja) 1996-01-31
DK0429624T3 (da) 1994-05-30
FI98707C (fi) 1997-08-11
AU5857490A (en) 1991-01-08
EP0429624A1 (fr) 1991-06-05
KR0179645B1 (en) 1999-03-20
WO1990015625A1 (fr) 1990-12-27
ES2053196T3 (es) 1994-07-16
US5246691A (en) 1993-09-21
US5246691C1 (en) 2001-10-09
CA2034484C (fr) 2000-08-15
FI98707B (fi) 1997-04-30
DE69007430T2 (de) 1994-07-07
FI910772A0 (fi) 1991-02-18
EP0429624B1 (fr) 1994-03-16

Similar Documents

Publication Publication Date Title
CA2034484A1 (fr) Radio-immunotherapie faisant appel a des emissions de particules-d
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
ZA878952B (en) Metal complex-containing pharmaceutical agents
RU93054941A (ru) Композиции, содержащие наночастицы, на поверхности которых адсорбирован тилоксапол, способ получения наночастиц, способ диагностики, применение наночастиц
HRP920632A2 (en) Oral composition for the treatment of inflammatory l deseases
GT199800126A (es) Terapia de combinacion.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
UA32577C2 (uk) Радіомічена сполука для утворення зображення тромбів при радіонуклідній діагностиці, радіофармацевтичний препарат та радіофармацевтична композиція на їх основі та комплект для приготування радіофармацевтичних препаратів
ATE113604T1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
EP0565668A4 (en) Biological stain composition, method of preparation and method of use for delineation of epitheleal cancer
ES2016343B3 (es) Composicion de agente de hinchamiento.
DK0482097T3 (da) Tensidpræparater og fremgangsmåder
NO894326L (no) Fremgangsmaate for fremstilling av et bifunksjonelt chelateringsmiddel.
GR3027668T3 (en) Immunosuppressive compositions
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
IT1167113B (it) Composizione farmaceutica contenente un composto di 1,4-benzochinone e suo impiego come agente antifibrotico
IT8249241A0 (it) Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione, utile per il trattamento dell'infarto miocardico
CA2206566A1 (fr) Technique et composition permettant de reduire le volume des tumeurs par une association de composes de platine et de tellure ou de selenium
DE3273389D1 (en) Derivatives of pentacyclo undecanes, processes for preparing these compounds, and pharmeceutical compositions thereof
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
EP0348664A3 (fr) Compositions pharmaceutiques contenant des monoacétoacétines pour le traitement des tumeurs
GR1003191B (el) Μεθοδος, συνθεση προσκευασματος (κιτ) και προσκευασμα (κιτ) για τη παρασκευη σε ενα σταδιο του συμπλοκου τεχνητιο 99μ (v) διμερκαπτοηλεκτρικο οξυ, για τη διαγνωση του μυελοειδους καρκινωματος του θυρεοειδους καθως και διαφορων ογκων
ES2118758T3 (es) Composiciones y metodo para tumores de tejidos blandos.
MX9700398A (es) Solucion para la modificacion de tumores cancerosos.
IT1280010B1 (it) Composizione farmaceutica a base di un complesso agente terapeutico/ matrice polimerica dotato di migliorate caratteristiche disapore

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry